PU3 is an Hsp90 inhibitor that competes with geldanamycin (GM) for binding to the conserved ATP/ADP pocket of Hsp90; it induces degradation of proteins such as Her2, causes hypophosphorylation of retinoblastoma protein, G1 cell cycle arrest, and cellular differentiation, thereby inhibiting breast cancer cell growth; it shows potential as an anticancer agent.